New research ‘supergroup’ looks to reduce the number of required clinical trials

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/ipopba)
(Image: Getty/ipopba)

Related tags: MMS Holdings, CRO, Contract research, Data collection, Real-world evidence

The MI-based CRO MMS Holdings is among the team at the Health Analytics Collective, a research group hoping to reduce the need for new clinical trials by using readily available data – and an MIT-incubated programming language.

According to the companies, the new health research “supergroup” aims to shorten the approval process for pharmaceutical and health care groups using real-world evidence (RWE) and other data sources.

Called the Health Analytics Collective, the group will be led by the Julia Lab within the MIT Computer Science and Artificial Intelligence Laboratory.

The team also includes the MI-based contract research organization (CRO) MMS Holdings, as well as the Center for Translational Medicine (CTM) at the University of Maryland School of Pharmacy, where the team will be based.  

“We have come together as a consortium to leverage our individual expertise in this area and are in discussions stages with some and execution stages with others for their proposed projects,” ​said MMS Chief Scientific Officer Dr. Uma Sharma.

Data sources will include the industry as well as patient databases, including both clinical and practice data, she told us.

“Utilizing data that is already available will alleviate the need for new clinical trials and hence speed up the approval process, also allowing for label enhancement of existing projects,”​ Sharma added.

Key to processing this data is Julia, an MIT-incubated programming language that is designed to solve computational problems quickly, according to the group.

Alan Edelman, Julia co-founder and professor of applied mathematics at MIT said, “We created this collective to forecast the future in health care and make critical decisions, giving data a longer life of more than just one use.”

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars